SCHEDULE 13G/A: Vensana Capital Affirms Significant Stake in CVRx, Inc. with Updated 13G Filing

Vensana Capital and its managing directors have filed an Amendment No. 3 to their Schedule 13G, confirming their beneficial ownership of over 7% of CVRx, Inc.'s common stock as of December 31, 2024.

Summary

• Vensana Capital I GP, LLC, Vensana Capital I, L.P., Kirk Nielsen, and Peter Justin Klein have filed an Amendment No. 3 to their Schedule 13G regarding their beneficial ownership in CVRx, Inc.
• As of December 31, 2024, Vensana Capital I GP, LLC, Vensana Capital I, L.P., and Peter Justin Klein each beneficially own 1,711,355 shares of CVRx, Inc. Common Stock, representing 7.1% of the class.
• Kirk Nielsen, a managing director of Vensana GP I and a director of CVRx, Inc., beneficially owns an aggregate of 1,760,734 shares, which includes 49,379 shares from exercisable stock options, representing 7.2% of the class.
• The percentages are calculated based on 24,263,663 shares of Common Stock outstanding as of October 25, 2024, as reported by CVRx, Inc. in its Form 10-Q for the quarter ended September 30, 2024, with Kirk Nielsen's percentage based on 24,313,042 shares (including his exercisable options).

Sentiment

Score: 5

Explanation: The document is a factual, routine disclosure of beneficial ownership and does not contain information that would significantly alter the perceived sentiment towards the company's operational or financial performance.

Positives

• Continued significant beneficial ownership by Vensana Capital and its managing directors indicates ongoing investment interest in CVRx, Inc.
• Kirk Nielsen, a director of CVRx, Inc., maintains a direct and indirect stake, aligning his interests with those of other shareholders.

Negatives

• No specific negative information is disclosed in this routine ownership update.

Risks

• No specific risks related to CVRx, Inc.'s operations or financial health are disclosed in this beneficial ownership filing.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding CVRx, Inc.'s future performance or outlook.

Industry Context

This filing is a routine disclosure of beneficial ownership by a passive investor group and does not provide specific insights into broader industry trends or competitive dynamics within the medical device sector.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant passive investor holdings and their voting/dispositive power.
• Management: Informs management of the continued significant stake held by Vensana Capital and its principals.

Key Dates

Keywords

CVRx Inc., Vensana Capital, Schedule 13G, beneficial ownership, common stock, investor filing, medical devices